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Abstract
Systemic lupus erythematosus (SLE) highlights the dangers of dysregulated B cells and the
importance of initiating and maintaining tolerance. In addition to central deletion, receptor editing,
peripheral deletion, receptor revision, anergy, and indifference, we have described a new
mechanism of B cell tolerance wherein dendritic cells (DCs) and macrophages (MΦs) regulate
autoreactive B cells during innate immune responses. In part, DCs and MΦs repress autoreactive
B cells by releasing IL-6 and soluble CD40L (sCD40L). This mechanism is selective in that IL-6
and sCD40L do not affect Ig secretion by naïve cells during innate immune responses, allowing
immunity in the absence of autoimmunity. In lupus-prone mice, DCs and MΦs are defective in
secretion of IL-6 and sCD40L and cannot effectively repress autoantibody secretion suggesting
that defects in DC/MΦ-mediated tolerance may contribute to the autoimmune phenotype. Further,
these studies suggest that reconstituting DCs and MΦs in SLE patients might restore regulation of
autoreactive B cells and provide an alternative to immunosuppressive therapies.
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Learning tolerance: a B cell’s story
A diverse B cell repertoire is critical in combating pathogens, but inherent in generating
diversity is the threat of autoimmunity. In the bone marrow, central tolerance mechanisms
such as deletion or receptor editing remove high-affinity autoreactive B cells before they
exit to the periphery [1–10]. Those that escape are subject to receptor revision [8, 11–14],
peripheral deletion [15, 16], or a shortened lifespan because they fail to enter B cell follicles
[17–22]. In rare cases, autoreactive B cells are fully functional but indifferent to their
specific antigen [23–25]. Finally, many low-affinity autoreactive B cells are maintained in
an unresponsive state known as anergy. Anergic B cells do not receive sufficient activation
signals to differentiate into plasma cells or secrete immunoglobulin (Ig) in response to
antigenic or mitogenic stimulation [26–29]. Their proliferative responses to B cell receptor
(BCR) or toll-like receptor (TLR) signaling as well as their lifespans vary in different
models [18, 30–35]. Some anergic B cells transduce BCR-derived signals [30, 32, 36–40],
while others exhibit desensitized BCRs [30, 33, 41]. Quiescence is dependent on chronic
exposure to self-antigen and occupancy of the BCR [42, 43]. Furthermore, ERK activation is
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critical in sustaining anergy during polyclonal stimulation by TLR ligands [27, 28].
Recently, it was demonstrated that anergy can be mediated by DCs and MΦs. In the
presence of TLR ligands, DCs and MΦs release IL-6 and sCD40L that selectively represses
Ig secretion from autoreactive B cells [44, 45]. In the absence of DCs/MΦs and their soluble
factors, autoreactive B cells regain the ability to secrete Ig, indicating that this mechanism of
tolerance is reversible. These data suggest that autoreactive B cells must be maintained in
close proximity to DCs/MΦs during innate immune responses to prevent autoimmunity.
The affinity and avidity of the antigen-BCR interaction determines whether developing B
cells will be deleted, edited, anergized, or ignored [46]. Self-reactive B cells that survive
these developmental checkpoints tend to bind self-antigens with low affinity and they
remain anergic in the absence of costimulation by cognate T cells. Many of the early
transgenic (Tg) models expressed BCRs with high affinities. However, concerns were raised
that these models may not adequately reflect how bona fide low-affinity self-antigens are
regulated [1, 26]. To study the tolerance mechanisms regulating low-affinity B cells, new Ig
Tg models were generated that expressed BCRs specific for double-stranded (ds) DNA,
single-stranded (ss) DNA, rheumatoid factor (RF), insulin, and Smith antigen (Sm).
A short history of Sm
Sm antigens are conserved proteins that are indispensable in RNA splicing. In 1966, Sm was
identified as a unique autoantigen, the first non-histone target of autoantibodies in systemic
lupus erythematosus (SLE) patients [47]. Named for 15-year-old Stephanie Smith,
antibodies to Sm became one of the diagnostic criteria for SLE [48], detectable in 5–30% of
SLE patients [48, 49]. Later studies correlated anti-Sm titers with kidney disease [50–53].
The autoantibodies isolated from patient sera proved invaluable in the initial studies of the
Sm proteins [54]. The small nuclear RNA (snRNA U1, U2, U4, or U5) in each small nuclear
ribonucleic particle (snRNP) is predicted to thread through the center of a heptameric ring of
Sm proteins (E, F, G, D1, D2, D3, and B/B’) [55]. Three of the Sm proteins (D1, B, and D3)
have long, positively charged tails that contact the pre-mRNA in the 5′ splice site region
[56]. This interaction stabilizes the commitment complex formed when U1 snRNP binds the
pre-mRNA substrate [57]. The remaining snRNPs, U2 and U4/U5/U6 (the triple snRNP)
bind to pre-mRNA, rearrange to form the splicesome, and remove introns from the transcript
[58].
Self-antigens composed of protein and DNA or RNA can co-ligate the BCR with TLRs,
potentially overcoming tolerance mechanisms and activating autoreactive B cells. For
example, concomitant ligation of the BCR and TLR9 by chromatin:IgG immune complexes
(ICs) activates RF-specific B cells in the absence of T cell help or overt TLR stimulation
[38, 59, 60]. Signaling through both the BCR and TLR9 is necessary to activate NF-κB in
these B cells [37]. Recently, RNA-IgG ICs were shown to activate RF-specific B cells via
TLR7 [39]. TLR7 binds ssRNA, a viral antigen that acts as a sensor of infection as well as a
component of the U1 snRNP splicing complex, a known autoantigen in SLE [61, 62].
Aberrantly high expression of TLR7, or an increased burden of ICs and/or apoptotic cells,
aggravates disease in lupus-prone mice. For instance, the gene duplication of TLR7 in Yaa
mice results in hyperactive B cells, exacerbation of disease in lupus-prone models, and shifts
autoantibody specificities to RNA [63, 64]. Reducing TLR7 gene expression ameliorates
disease and increases survival [63]. Hence, the combination of self-proteins and TLR
ligands within ICs and on the surface of apoptotic cells can mistakenly activate autoreactive
B cells and result in autoimmunity.
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Arresting and silencing Sm-specific B cells
Sm-specific autoantibodies are a hallmark of both human and murine lupus. To identify the
mechanisms that regulate Sm-specific B cells, the 2–12H Tg mice were generated [35, 65].
In this model, an Ig heavy chain, 2–12H, was identified from an Sm-specific hybridoma
derived from an MRL/lpr mouse. The 2–12H chain pairs with a variety of light chains,
giving rise to B cells specific for Sm and/or ss-DNA. B cells from the 2–12H model express
BCRs of multiple affinities that develop and are regulated on a non-autoimmune
background.
Tolerance to Sm is dependent on several cell types. B cells are the most obvious suspects in
SLE since disease pathology is mediated by autoantibodies. In vivo, Sm-specific B cells are
regulated since 2–12H Tg mice have low titers of anti-Sm antibodies [35, 66]. However, ex
vivo non-subsetted 2–12H B cells (uncontaminated by DCs and MΦs) are activated by TLR
stimulation (LPS, CpG, dsRNA) in vitro but their Ig secretion is lower than that of C57BL/6
controls [35, 67]. The follicular (FO) B cell subset is repressed by DCs and MΦs secreting
IL-6 and sCD40L, while secretion by the MZ B cell subset is partially repressed, but only by
MΦs and sCD40L [45]. Some MZ B cells and peritoneal B-1 cells ignore endogenous levels
of Sm, but an increase in the number of apoptotic cells can activate peritoneal and MZ B
cells [66, 68, 69]. Sm-specific B cells arrested at the pre-plasma cell stage, interrupting
plasma cell differentiation and preventing Ig secretion [32].
Restricting the light chain that pairs with 2–12H allowed for the analysis of Sm-specific B
cells of moderate and low affinity [32, 70]. The 2–12H/Vκ4 Tg mouse was generated to
examine regulation of higher affinity anti-Sm responses [70]. B cells from this mouse are
distributed among splenic transitional, FO, and MZ subsets, as well as the peritoneal B-1
subset [70]. 2–12H/Vκ4 B cells are anergic and all subsets are hyporesponsive to LPS in
vitro. Additionally, MZ B cells exhibit a block in BCR signaling [70]. LPS-stimulated 2–
12H/Vκ4 B cells are repressed by IL-6 and sCD40L (unpublished data). To study low-
affinity anti-Sm responses, the 2–12H/Vκ8 Tg mouse was created [32]. In this model, only
transitional and FO B cells are present and these cells are regulated by anergy [32]. As in the
previous anti-Sm models, 2–12H/Vκ8 B cells are susceptible to IL-6- and sCD40L-mediated
repression [44, 45].
T cells are implicated in SLE and Sm-specific T cells are present in the repertoires of both
normal and autoimmune mice [71]. Sm-specific T cells in 2–12H Tg mice are anergic and
do not proliferate in response to B cells presenting Sm [71]. Anergic T cells are also unable
to upregulate CD40L and provide costimulation to their cognate B cells [72]. Anti-Sm B
cells do not secrete Ig in vivo [35, 65], perhaps because they are deprived of T cell
costimulation. However, in autoimmune situations, autoreactive T cells induce class-
switching and somatic hypermutation of anti-Sm B cells, resulting in high levels of
pathogenic high-affinity IgG autoantibodies [73, 74]. Paradoxically, anti-Sm B cells are
required to tolerize Sm-specific T cells from C57BL/6 mice, but they activate Sm-specific T
cells from MRL/lpr mice [71, 75, 76]. This indicates that although T cells are necessary for
the development of autoantibodies and disease, they are also regulated by autoreactive B
cells in normal individuals.
DCs and MΦs regulate innate and adaptive immune responses by tolerizing or activating T
and B cells. The continued ingestion and presentation of self-antigens or the acute
presentation of foreign antigen by DCs/MΦs either tolerizes or activates T cells to drive
adaptive immune response. The activation of DCs during innate immune responses induces
the secretion of IL-6 that promotes immunity by releasing CD4+ T-helper cells from their
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inhibitory functions [77]. This promotes polyclonal activation of naive B cells, the
production of neutralizing antibody and the clearance of the invading pathogen.
In addition to regulating T cells, DCs and MΦs affect the fate of B cells. They activate naïve
B cells by secreting type I interferon, IL-6, and B lymphocyte stimulator (BLyS) [78–80].
They also repress Ig secretion by B cells that have been chronically exposed to antigen. Our
laboratory showed that DCs and MΦs regulate autoantibody production, in part through
their secretion of IL-6 and sCD40L [44, 45]. Repression is selective in that naïve B cells
(not chronically exposed to antigen) are unaffected by the presence of IL-6 and sCD40L
while Ig secretion by autoreactive B cells is repressed (Fig. 1a). Coupled with the data
showing that IL-6 de-represses regulatory T cells, a mechanism emerges explaining how the
pleiotropic affects of IL-6 produced by DCs and MΦs simultaneously promotes immunity
and represses autoimmunity during innate immune responses. Signal transduction through
many cell surface receptors influences neighboring receptors.
For example, crosstalk between the IFN-αβ and IL-6 receptor (IL-6R) signaling pathways
augment transcription factor binding and gene expression in mouse embryonic fibroblasts
(MEFs) [81]. Similarly, stimulation of B cells with sCD40L, IL-4, and LPS reprograms the
BCR signaling pathway, enhancing ERK activation and bypassing the requirement for
phosphatidylinositol 3-kinase (PI3-K) [82–86]. The findings that only B cells chronically
exposed to self-antigen are susceptible to repression by IL-6 and sCD40L suggests that
chronic BCR-derived signals “reprogram” the outcome of IL-6R and CD40 signal
transduction. On a molecular level, the ability of IL-6 and sCD40L to repress Ig secretion
reflects diminished BLIMP-1 and XBP-1 mRNA and protein levels. These data indicate that
regulation occurs upstream of transcriptional activation. In support of this,
pharmacologically inhibiting MEK restores LPS-induced Ig secretion. This suggests that the
ability of IL-6/sCD40L to repress TLR4-induced Ig secretion is MEK/ERK-dependent
(unpublished data).
Susceptibility of B cells to IL-6/sCD40L requires that B cells be chronically exposed to
antigen, consistent with a central role for the BCR in tolerance. High-affinity neo-self-
antigens direct a unique tolerance scheme compared to low-affinity self-antigens. Anergic B
cells from high-affinity models are characterized by elevated phospho-ERK [42, 87]. In
addition, the binding of high-affinity antigen to the BCR and constitutive MEK/ERK
activation is sufficient to repress TLR4 and TLR9-induced Ig secretion [27, 28]. In the low-
affinity Sm model (2–12H/Vκ8) basal phospho-ERK levels are comparable to those in the
HEL model. However, unlike the HEL model, the binding of soluble SmD or snRNPs
coupled with elevated phospho-ERK levels does not repress TLR-induced Ig secretion
(unpublished data). This indicates that ERK is only part of the “BCR-derived” signals that
regulate innate immune responses in vivo. Although B cells expressing high-affinity
receptors can be repressed by IL-6 and sCD40L, antigen stimulation is sufficient. In
contrast, B cells expressing low-affinity receptors for bona fide self-antigens (Sm and
ssDNA) do not achieve sufficient BCR-derived signals to influence TLR4-induced Ig
secretion and depend on additional signals from IL-6/sCD40L (unpublished data).
The finding that DCs secrete IL-6 while MΦs secrete IL-6 and sCD40L suggests that the
anatomic location within the secondary lymphoid organs might dictate how autoreactive B
cells are regulated. Marginal zone B cells are solely repressed by sCD40L while FO B cells
are repressed by IL-6 and sCD40L [45]. This specificity may result from the anatomic
location, since different subsets of DCs and MΦs localize to specific regions of the spleen.
For example, B cells are retained in the marginal zone by MΦs [88] and they are regulated
by MΦ-derived sCD40L. However, upon activation and differentiation into pre-plasma
cells, they may become susceptible to repression by IL-6 secreted by DCs within the
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periarteriolar lymphoid sheath (PALS). Thus, depending on the anatomic location of the
autoreactive B cell, DCs and/or MΦs can repress autoantibody production during innate
immune responses.
Failed tolerance: Sm-specific autoantibodies in a murine model of SLE
MRL/lpr mice are a well-characterized murine model of SLE, with adult-onset disease
mediated by autoantibody deposition and tissue destruction. The prevalence of anti-Sm
autoantibodies in human SLE patients and MRL/lpr mice is approximately 25% [89, 90].
BCR Tg models have been bred onto the MRL background, allowing B cells of known
specificities to be followed throughout development. Developmental arrest, FO exclusion,
and receptor editing are defective in MRL/lpr mice [91, 92]. Expression of the 2–12H
transgene in MRL/lpr mice increases the prevalence of the anti-Sm response, accelerates
disease, and leads to higher serum anti-Sm levels [65]. Sm-specific B cells from 2–12H
mice are arrested at the pre-plasma cell stage, while B cells from the 2–12H/MRL/lpr mice
bypass this checkpoint and become activated [93].
The presence of class-switched autoantibodies in MRL/lpr mice suggests a breakdown in
tolerance within the adaptive immune response. In MRL/lpr mice where somatic
hypermutation and isotype switch recombination are blocked (AID−/−), lupus-like symptoms
such as glomerulonephritis, proteinuria, and immune complex deposition are ameliorated
[94]. Early studies showed a critical role for T cells in disease because thymectomized
MRL/lpr mice failed to develop lupus-like disease [95]. Subsequently, it was shown that
defects in central deletion and the number and function of T-regulatory cells allow CD4+ T-
helper cells to activate autoreactive B cells, induce terminal differentiation and autoantibody
production [96–101].
Dysregulation of the innate immune system is apparent in MRL/lpr mice [39]. ICs
containing RNA or chromatin stimulate RF-specific B cells through TLR7 and TLR9 to
secrete anti-Sm and anti-chromatin [38, 39]. Consistent with a role for TLRs, autoantibody
responses were reduced in MyD88−/−/MRL/lpr mice [39] and disease was ameliorated
[102]. TLR7−/−/MRL/lpr mice exhibit reduced autoantibody titer and gene duplication of
TLR7 shifts autoantibody specificities toward RNA, exacerbating disease [63, 64]. This
reveals TLR7 as a key receptor in promoting autoimmunity when tolerance is overcome [63,
103]. Like TLR7−/−/MRL/lpr mice, TLR9−/−/MRL/lpr mice exhibited lower titers of anti-
DNA autoantibodies. However unlike TLR7−/−/MRL/lpr mice, they remain plagued by
accelerated kidney disease and increased mortality [103]. These data suggest that TLR9
induces anti-DNA responses but also has an anti-inflammatory effect, possibly through its
induction of regulatory T cells [104, 105]. The function of regulatory T cells in TLR9−/−/
MRL/lpr mice is impaired, potentially allowing autoreactive cells to exacerbate disease
[106]. These data indicate that innate immune responses have tremendous and opposing
effects on autoantibody production and disease in MRL/lpr mice.
Defects in DC/MΦ-mediated tolerance are evident in lupus-prone mice. Our studies indicate
that secretion of IL-6 and sCD40L by DCs/MΦs, as well as reprograming of IL-6R and
CD40 in autoreactive B cells, promote tolerance during innate immune responses. This
implies that defects in either the secretion of IL-6/sCD40L or the selective response of
autoreactive B cells to these factors regulate autoantibody production. Our studies indicate
that DCs and MΦs from MRL/lpr mice are unable to repress autoreactive B cells (Fig. 1b).
Defects in DC/MΦ-mediated repression are coincident with diminished secretion of IL-6
and sCD40L and failure to sustain IL-6 mRNA production and activation of the IκB/NFκB
pathways [107]. Similarly, we found that IL-6 and sCD40L fail to repress B cells from
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lupus-prone mice (unpublished data). The finding that lupus-prone mice harbor defects in
DCs/MΦs and B cells suggests the influence of an environmental stimulus.
Apoptotic cells: dangerous in death
Apoptotic cells pose a unique challenge to the immune system since they are a rich source of
nuclear antigens, including DNA, ICs, nucleosomes, histones, snRNPs and snRNAs, Ro, La,
and Sm. These self-antigens can be modified by phosphorylation and/or alternate protein
cleavage, revealing novel epitopes that were not available during the induction of B and T
cell tolerance [108–111]. During cell death, self-antigens are distributed in large and small
blebs on the cell surface and act as targets for autoreactive B cells in a membrane-bound,
multimeric form [112–114]. The display of self-antigens on apoptotic cells is necessary to
develop autoantibodies. For instance, autoantibodies to cytoplasmic but not nuclear antigens
develop when nuclear fragmentation is blocked in apoptotic cells [115]. Therefore, it is
imperative that scavenger cells such as MΦs and DCs quickly clear apoptotic cells and their
associated self-antigens to minimize inflammatory and autoimmune responses.
Apoptotic cells are bound and cleared by a variety of receptors on DCs and MΦs. Ingestion
of apoptotic cells reduces the secretion of proinflammatory cytokines by DCs and MΦs,
inhibiting their maturation and controlling the activation of T cells and autoimmune
responses to apoptotic cells [116–121]. Decreased clearance of apoptotic cells and defects in
phagocytosis by MΦs in SLE patients and lupus-prone mice may lead to autoimmunity [69,
108, 122–124]. The increase in apoptotic cells and antigens could dysregulate DCs and
MΦs, triggering a chronic anti-inflammatory response that downregulates the production of
cytokines important for B cell tolerance [45, 107].
If apoptotic cells fail to be cleared efficiently, they may become necrotic and expel self-
antigens and TLR ligands that are opsonized by autoantibodies, forming ICs [125, 126].
Like apoptotic cells, ICs present self-antigens in a multimeric form and enhance
phagocytosis by DCs and MΦs [127, 128]. While apoptotic cells stimulate anti-
inflammatory responses, ICs bind to Fc receptors (FcRs) and elicit inflammatory responses
from MΦs and DCs [128]. Individual FcRs have distinct activating and inhibitory functions
to ensure balance in a normal immune system. Activating FcRs include FcγRI and FcγRIII,
which phagocytose ICs and provoke inflammatory responses from DCs and MΦs [129–
131]. These receptors are necessary and sufficient for glomerulonephritis in (NZB/NZW) F1
mice [132–134]. Co-ligation of TLR9 and FcγRIII by chromatin:IC induces more DC
activation than ligation of FcγRIII alone, indicating that TLRs synergize with FcR signaling
[135]. In contrast to the activating FcRs, FcγRIIB is an inhibitory FcR with various
functions depending on cell type. It modulates MΦ phagocytosis, DC maturation, BCR
signaling, IgG secretion, and the expansion of autoreactive IgG-producing B cells [134,
136–145]. Autoantibodies and glomerulonephritis develop in certain strains of mice
deficient in FcγRIIB, affirming its role in preventing autoreactive B cell activation [146,
147]. Additionally, antigen internalized by DCs through FcγRIIB, but not FcγRI or
FcγRIII, is presented in its native form and activates antigen-specific B cells [148]. ICs and
FcRs have important roles in the immune system, but their dysregulation can result in
autoantibody secretion and nephritis.
Clearance of apoptotic cells and their associated autoantigens is crucial in preventing
activation of B cells, DCs, MΦs, and T cells. When mice are immunized with apoptotic cells
or exhibit a defect in apoptotic cell clearance, Sm-specific antibodies are detectable in the
serum and MZ and B-1 B cells are inappropriately activated [66, 68, 69]. This suggests that
recognition of autoantigens on apoptotic cells can drive B cell terminal differentiation [66,
68]. Impaired clearance of apoptotic cells in Faslpr [69] and merkd [149, 150] mice prevents
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BCR-mediated reprograming of IL-6R and CD40 (unpublished data). These data suggest
that exposure of autoreactive B cells to apoptotic cells or ICs can impact DC/MΦ-mediated
tolerance. In summary, apoptotic cells and the self-antigens they display can play both
autoimmune and anti-inflammatory roles. Imbalances in apoptotic cell clearance or cellular
responses result in inflammatory responses and autoimmune disease.
Selective repression: new treatments for SLE?
Systemic lupus erythematosus is primarily a B cell-mediated autoimmune disease, with
symptoms arising from autoantibody deposition and inflammation in target organs, such as
the kidneys, skin, and brain. Until recently, treatments for SLE were dependent on
immunosuppression, which depresses immune function and causes dangerous side effects
such as opportunistic infections [151]. Therapies that target specific cell types or biologic
processes are now being developed, with the hopes that they will be more powerful and have
less harmful side effects. For instance, chimeric anti-CD20 (rituximab), depletes peripheral
B cells and reduces the severity of SLE symptoms in many patients [152]. However, a
subset of patients is resistant to rituximab treatment [151]. Additionally, rituximab recently
failed a late-stage study when its efficacy in achieving a clinical response was no greater
than a placebo [153]. In murine studies of human CD20, B cells in autoimmune-prone
strains were refractory to depletion by rituximab [154], compared to non-autoimmune-prone
strains. Other biologic agents being studied or developed target complement activation, B
cell-T cell interactions, cytokines, TLRs, interferon, or direct removal of antibodies from
circulation. However, developing therapies to target each lupus-related autoantigen would
be cumber-some and slow. A more efficient approach would be a therapy that selectively
targeted autoreactive B cells through a common trait to restore tolerance. In previous
studies, we determined that DC- and MΦ-mediated repression via IL-6 and sCD40L is
effective on B cells of multiple specificities. These data suggest that any B cell chronically
exposed to antigen would be susceptible to DC/MΦ-mediated tolerance. We are currently
determining whether the lack of these soluble factors promotes autoimmunity in normal
mice during innate immune responses. Preliminary data indicate that Sm-specific B cells
adoptively transferred into chimeric mice lacking IL-6 and sCD40L become activated and
secrete autoantibodies (unpublished data). This is consistent with our model indicating that
DCs/MΦs and their secreted products regulate autoreactive B cells during innate immune
responses. Future experiments will examine if tolerance can be restored in lupus-prone mice
reconstituted with a mix of autoimmune and non-autoimmune hematopoietic stem cells. If
DC/MΦ-mediated tolerance is found to be defective in SLE patients, future therapies could
target their in vivo activation or introduce normal DCs/MΦs to reinstate B cell tolerance of
newly emerging B cells following B cell depletion therapy. One approach would be non-
myeloablative bone marrow transplant (BMT) or nonmyeloablative hematopoietic stem cell
transplant (HSCT) to promote mixed chimerism. This may reinstate tolerance by providing a
pool of DCs/MΦs that repress autoreactive B cells. Such an approach has shown promise in
controlling B cell-mediated autoimmune disease in humans and mouse models [155–160],
resulting in remission of rheumatoid arthritis in a human patient [158] and reduction in
lupus-like disease in mice [155, 157].
Summary
The autoreactive B cells that incite multi-organ damage in SLE patients become
dysregulated long before clinical symptoms appear. Autoantigens and TLR ligands released
from apoptotic cells can overcome the tolerance of autoreactive B cells. Autoreactive T cells
provide costimulation and promote the secretion of high-affinity, class-switched
autoantibodies. These autoantibodies can bind nuclear self-antigens, form ICs, and provoke
inflammatory responses from DCs and MΦs. Fortunately, DCs and MΦs specifically repress
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autoreactive B cells during TLR stimulation by secreting IL-6 and sCD40L. Restoring
normal DC and MΦ function in SLE patients might repress autoreactive B cells and re-
establish balance among the complex components of the immune system.
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DCs and MΦs repress antibody secretion from autoreactive B cells via IL-6 and sCD40L.
(a) In non-autoimmune mice, B cell tolerance is maintained during innate immune responses
by DCs and MΦs. Although TLR stimulation promotes Ig secretion by B cells, it
simultaneously induces DCs and MΦs to secrete IL-6 and sCD40L. These soluble factors
repress Ig secretion from autoreactive B cells while allowing innate stimuli to produce a
polyclonal response by naïve B cells. (b) In lupus-prone mice, DCs and MΦs are defective
in the production of IL-6 and sCD40L, allowing both autoreactive and naïve B cells to
produce Ig in response to TLR stimulation
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